Jefferies Financial Group Inc. Has $53.13 Million Holdings in Immatics N.V. $IMTX

Jefferies Financial Group Inc. boosted its stake in shares of Immatics N.V. (NASDAQ:IMTX) by 323.4% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 5,059,551 shares of the company’s stock after purchasing an additional 3,864,636 shares during the quarter. Jefferies Financial Group Inc. owned 4.16% of Immatics worth $53,125,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of the stock. Bank of America Corp DE raised its stake in Immatics by 166.0% during the 4th quarter. Bank of America Corp DE now owns 3,575 shares of the company’s stock valued at $25,000 after purchasing an additional 2,231 shares during the last quarter. Vanguard Personalized Indexing Management LLC raised its stake in Immatics by 8.3% during the 3rd quarter. Vanguard Personalized Indexing Management LLC now owns 47,635 shares of the company’s stock valued at $406,000 after purchasing an additional 3,666 shares during the last quarter. Insigneo Advisory Services LLC acquired a new position in Immatics during the 3rd quarter valued at $103,000. Engineers Gate Manager LP acquired a new position in Immatics during the 2nd quarter valued at $124,000. Finally, BNP Paribas Financial Markets raised its stake in Immatics by 105.2% during the 2nd quarter. BNP Paribas Financial Markets now owns 78,123 shares of the company’s stock valued at $420,000 after purchasing an additional 40,058 shares during the last quarter. 64.41% of the stock is currently owned by institutional investors and hedge funds.

Immatics Stock Performance

Shares of IMTX stock opened at $11.62 on Friday. Immatics N.V. has a 52-week low of $4.93 and a 52-week high of $12.41. The stock has a market cap of $1.56 billion, a price-to-earnings ratio of -5.84 and a beta of 1.31. The firm has a fifty day moving average of $10.58 and a 200-day moving average of $10.19.

Immatics (NASDAQ:IMTX) last announced its quarterly earnings data on Tuesday, May 12th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.08). Immatics had a negative net margin of 572.35% and a negative return on equity of 47.36%. The business had revenue of $8.81 million during the quarter, compared to analyst estimates of $9.79 million. On average, sell-side analysts predict that Immatics N.V. will post -1.75 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities analysts recently commented on IMTX shares. Mizuho set a $25.00 target price on shares of Immatics in a research note on Thursday, February 19th. TD Cowen initiated coverage on shares of Immatics in a research note on Tuesday, April 28th. They issued a “buy” rating for the company. Jefferies Financial Group initiated coverage on shares of Immatics in a research note on Monday, March 16th. They issued a “buy” rating and a $18.00 price objective for the company. Chardan Capital restated a “buy” rating and issued a $25.00 price objective on shares of Immatics in a research note on Tuesday, May 19th. Finally, Wall Street Zen cut shares of Immatics from a “hold” rating to a “sell” rating in a research note on Saturday, May 2nd. Seven investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Immatics presently has a consensus rating of “Moderate Buy” and a consensus target price of $19.00.

Immatics Company Profile

Immatics N.V. (NASDAQ: IMTX) is a clinical-stage biotechnology company dedicated to the development of T cell receptor (TCR)-based immunotherapies for solid tumors. The company leverages its proprietary discovery and engineering platforms to identify tumor-specific peptide targets and develop therapies that harness the power of a patient’s immune system. Immatics’ approach aims to generate durable responses by guiding T cells to recognize and kill cancer cells with high precision.

At the core of Immatics’ technology suite is the XPRESIDENT® platform, which mines the cancer peptidome to uncover novel tumor antigens naturally presented on the surface of cancer cells.